• Policy
• On-site inspections of overseas plants will resume next year
• by Lee, Hye-Kyung Sep 23, 2022 05:52am

• Policy
• Leclaza to receive first monitoring for PVA negotiations
• by Lee, Tak-Sun Sep 23, 2022 05:52am

• Policy
• Janssen's Imbruvica succeeded in setting a standard
• by Lee, Tak-Sun Sep 22, 2022 06:02am

• Policy
• MOHW's advisory council to respond to US’s Bio initiative
• by Lee, Jeong-Hwan Sep 21, 2022 05:47am

• Policy
• Domestic authorization for the Quadrivial Adjuvant Flu Vac
• by Lee, Tak-Sun Sep 21, 2022 05:47am

• Policy
• 23 items have been designated as Fast Tracks in 2yrs
• by Lee, Hye-Kyung Sep 21, 2022 05:47am

• Policy
• GOV engrossed in minimizing damage from US's Bio Initiative
• by Lee, Jeong-Hwan Sep 20, 2022 05:57am

• Policy
• 37 Tenelia's generics will soon be listed
• by Lee, Tak-Sun Sep 20, 2022 05:57am

• Policy
• NHIS negotiations complete for Erbitux·Zerbaxa·Eylea
• by Lee, Tak-Sun Sep 20, 2022 05:56am

• Policy
• Empagliflozin's permission changes
• by Lee, Hye-Kyung Sep 19, 2022 05:56am